Examining Peanut Allergy Pathophysiology, Immunotherapy Data, and Health Care Utilization is organized by Pharmacy Times Continuing Education (PTCE).
Release Date: June 5, 2019
Expiration Date: June 5, 2020
Specialty Pharmacists and Managed Care Professionals.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs)
With peanut allergies affecting about 2.5% of children and 1.2% of the US population overall, it is the most common food allergy in children and a leading cause of allergy-related death. Its prevalence has tripled in a decade, and only 20% of children are expected to outgrow their peanut allergy pointing to a continued increase in peanut allergy-related costs to the healthcare system. Rising incidence of anaphylaxis has triggered an increase in health care resource utilization such as emergency department visits and a reduction in the quality of life for a growing number of patients. Most of the efforts to move treatment toward proactively addressing peanut allergies using immunotherapy are focused on desensitization. Specialty pharmacists will be involved in the dispensing of treatments for patients with peanut allergies and can advise patients and caregivers about adverse effects and monitor for adverse events that may discourage utilization. Availability of new immunotherapies also opens the opportunity for pharmacy benefit management professionals to play a proactive role in developing drug benefit management strategies that support the identification of patients and appropriate immunotherapies to reduce health care resource utilization as well as help patients control their allergies and improve their quality of life.
At the completion of this activity, the participant will be able to:
• Characterize the prevalence and demographic patterns of peanut allergies in the United States
• Explain the pathophysiology and immunological response in peanut allergies
• Examine emerging immunotherapies and clarify data associated with peanut allergy clinical trial end points
• Apply knowledge of novel immunotherapies and desensitization to improve patient quality of care upon integration of peanut allergy immunotherapies into the treatment paradigm.
Pediatrics Allergy and Immunology, Pathology, Physiology and Biophysics